{"id":"W2795150236","doi":"10.2217/fon-2018-0121","title":"Accelerating Drug Development in Pediatric Cancer: A Novel Phase I Study Design of Venetoclax in Relapsed/Refractory Malignancies","year":2018,"lang":"en","type":"article","venue":"Future Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Celgene; Sanofi; Genentech; Ariad Pharmaceuticals; Amgen","keywords":"Venetoclax; Medicine; Clinical trial; Refractory (planetary science); Oncology; Internal medicine; Drug development; Chronic lymphocytic leukemia; Chemotherapy; Cancer; Drug; Leukemia; Pharmacology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003242641,0.0008893522,0.001259406,0.0003606791,0.0004438518,0.001108071,0.0005893068,0.001031783,0.005998425],"category_scores_gemma":[0.001682878,0.0004160709,0.001162951,0.0004326412,0.0006206364,0.0008368762,0.0004483633,0.002762962,0.000821829],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007372733,"about_ca_system_score_gemma":0.003861179,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005278023,"about_ca_topic_score_gemma":0.002086293,"domain_scores_codex":[0.9991274,0.000490867,0.00004861627,0.0001378416,0.00006843633,0.0001268014],"domain_scores_gemma":[0.9991386,0.000156318,0.0001713426,0.0001157777,0.0001129106,0.0003049766],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4542416,0.1039446,0.01087568,0.003235728,0.002057294,0.0008259684,0.0009983063,0.007787378,0.120026,0.007509308,0.01504633,0.2734517],"study_design_scores_gemma":[0.3559322,0.5670363,0.006833122,0.0002261878,0.001623434,0.0007592523,0.0001594658,0.004338278,0.01563365,0.001842959,0.04554956,0.00006563222],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9145941,0.005193626,0.01286507,0.00221817,0.0007316656,0.0527349,0.003163842,0.0002114494,0.008287278],"genre_scores_gemma":[0.8583454,0.007488488,0.05101257,0.003035917,0.0005072664,0.0684733,0.002257173,0.00009792967,0.008781956],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005998425,"threshold_uncertainty_score":0.02006674,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06121352229830328,"score_gpt":0.3801271580229051,"score_spread":0.3189136357246018,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}